BPC-157
This scoping review aims to evaluate the molecular mechanisms, therapeutic potential, and safety concerns of Body Protective Compound-157 (BPC-157) in the context of musculoskeletal healing. Given the compound’s increasing availability, popularity, and its regulatory controversies, we sought to assess the breadth and quality of preclinical and clinical data supporting its use in musculoskeletal medicine.
Recent Findings
BPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice and has demonstrated regenerative properties across numerous animal models. It activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis, promoting angiogenesis, fibroblast activity, and neuromuscular stabilization. It also engages ERK1/2 signaling, facilitates endothelial and muscle repair, and exerts anti-inflammatory effects. These effects promote angiogenesis, fibroblast activity, and neuromuscular stabilization, particularly in poorly vascularized tissues such as tendons and myotendinous junctions. Despite broad preclinical support, human data are extremely limited. Only three pilot studies have examined BPC-157 in humans, including its use for intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics. No adverse effects were reported, but rigorous, large-scale trials are lacking.
Summary
BPC-157 demonstrates robust regenerative and cytoprotective effects in preclinical studies, positioning it as a potentially valuable tool in musculoskeletal medicine. Despite its growing popularity among athletes and its wide availability through non-regulated sources, there is minimal human data available. Until well-designed clinical trials are conducted, BPC-157 should be considered investigational, and its use approached with caution. This review highlights that given the robust preclinical evidence and high public interest, there is a critical need for well-designed human trials to assess the safety, efficacy, and clinical utility of BPC-157 in musculoskeletal medicine.
Introduction
Peptide therapy is an emerging area of research in musculoskeletal medicine. Peptides, naturally occurring short chains of amino acids synthesized in the body, act as selective signaling molecules that bind to specific cell surface receptors, triggering intracellular cascades [1]. Peptides play a crucial role in various biological functions and have been widely applied in drug development over the past decade [2]. Given their ability to regulate physiological mechanisms, research has increasingly focused on harnessing naturally-occurring peptides to develop new therapeutic tools [3]. Among peptides studied for tissue and muscle repair [4, 5], BPC-157 (also known as PLD-116, PL-10, PL14736, or Bepectin [6–9]) has gained attention [10, 11]. Originally isolated from human gastric juice by Dr. Predrag Sikiric in 1993, BPC-157 has demonstrated regenerative properties in animal models, promoting the healing of tendons, ligaments, muscles, nerves, bones, teeth, corneas, and the endothelium [15–29]. Studies also suggest it may be hepatoprotective, aid recovery from traumatic brain injury, and influence blood clot formation/degradation [
Be the first to review “BPC-157”
Related products
PEPTIDES
PEPTIDES
PEPTIDES
PEPTIDES
PEPTIDES
PEPTIDES
PEPTIDES
PEPTIDES
Reviews
There are no reviews yet.